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Abstract
Microtubule stabilizers are powerful anti-mitotic compounds and represent a proven cancer
treatment strategy. Several classes of compounds in clinical use or trials, such as the taxanes and
epothilones, bind to the same region of β-tubulin. Determining how these molecules interact with
tubulin and stabilize microtubules is important both for understanding the mechanism of action
and enhancing chemotherapeutic potential, e.g. reducing side effects, increasing solubility, and
overcoming resistance. Structural studies using nonpolymerized tubulin or stabilized polymers
have produced different models of epothilone binding. Here, we used directed mutagenesis of the
binding site on Saccharomyces cerevisiae β-tubulin to analyze interactions between Epothilone B
and its biologically relevant substrate, dynamic microtubules. Five engineered amino acid changes
contributed to a 125-fold increase in Epothilone B cytotoxicity independent of inherent
microtubule stability. The mutagenesis of endogenous β-tubulin was done in otherwise isogenic
strains. This facilitated the correlation of amino acid substitutions with altered cytotoxicity using
molecular mechanics simulations. The results, which are based on the interaction between
Epothilone B and dynamic microtubules, most strongly support the binding mode determined by
NMR spectroscopy-based studies. This work establishes a system for discriminating between
potential binding modes and among various compounds and/or analogues using a sensitive
biological activity-based readout.
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Introduction
Anti-mitotic compounds that bind tubulin and disrupt microtubule dynamics provide for
important cancer therapies, and understanding the molecular mechanisms of these
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compounds holds the promise of optimizing and exploiting this clinically proven strategy.
The taxanes represent an important class of anti-cancer agents, e.g. paclitaxel and docetaxel,
that produce cytotoxicity by enhancing the assembly of tubulin, stabilizing microtubules,
suppressing microtubule dynamics, and causing mitotic arrest and apoptosis.[1] The
epothilones are a group of natural products produced by the myxobacterium Sorangium
cellulosum[2] that bind to tubulin in microtubules at a site that overlaps with the paclitaxel
site, and generate cytotoxicity through a similar mechanism.[3, 4] An attractive property of
the epothilones is that they may retain excellent activity against cells that have become
resistant to the taxanes due to over-expression of the multi-drug transporter.[3–5] Currently
Epothilone B (EpoB, Fig. 1) and various epothilone analogues are in clinical trials[6] and
Ixabepilone is approved for use against some cancers. However, the molecular interactions
of the epothilones with tubulin/microtubules remain unclear.
The region of β-tubulin that binds to the taxanes and epothilones can exert powerful
influence over microtubule dynamics. Moreover, the knowledge of the molecular details at
this site carries significant clinical potential. Our current understanding of how taxanes and
epothilones interact with β-tubulin comes mainly from the electron crystal (EC) structures of
complexes between the compounds and a tubulin polymer induced by zinc ions,[7, 8] and
from NMR spectroscopy,[9, 10] supported by structure-activity relationship analysis
(SAR)[11] and molecular modeling efforts.[12] Although the two classes of compounds
compete with each other for binding[3, 4] and bind to the same cavity in β-tubulin,[3, 4] the
EC structures of the drug-tubulin polymer complexes have shown that the binding
interactions are not identical.[7, 8] This is also reflected in results with wild-type yeast
tubulin. EpoB binds to Saccharomyces cerevisiae tubulin, but paclitaxel does not.[13]
Two strikingly distinct models of Epothilone binding to tubulin have been generated using
an NMR[10] based approach or EC[7] derived measurements at ~3 Å resolution which was
not adequate to directly define the bound conformation. Thus there is a need to determine
the active conformation of tubulin-bound epothilone using structure-activity approaches. To
date, SAR data for the epothilones have been limited to ligand binding studies with wild-
type tubulin, or spontaneously occurring tubulin mutations in tumor or culture cell lines.
Alternatively, site-directed mutagenesis of endogenous tubulin would allow controlled
analysis of the epothilone-binding pocket. By converting five residues in S. cerevisiae β-
tubulin to those of mammalian brain tubulin, we were able to impart paclitaxel-binding
activity to budding yeast tubulin.[14, 15] Here we report that the five amino acid changes that
confer paclitaxel binding to yeast tubulin drastically increase the cytotoxicity of EpoB,
indicating that the interactions that mediate the potency of both compounds may be more
similar than previously predicted based on electron crystallography.[7] These changes,
Ala19Lys, Thr23Val, Gly26Asp, Asn227His, and Tyr270Phe allowed the role of each of
these residues to be individually examined. This effect was cumulatively mediated by the
five substitutions. Thus, we were able to utilize molecular modeling simulations to
distinguish between the current models for the binding of EpoB to tubulin.
Results and Discussion
Mutations in the taxane-binding region of β-tubulin mediate EpoB cytotoxicity
We found that changing five amino acids in the yeast β-tubulin EpoB binding pocket to
those found in bovine brain tubulin (Tub2-BBBBB) increased the cytotoxicity of EpoB for
these cells by 125-fold (Table 1). The ED50 for cells with wild-type tubulin (Tub2-YYYYY)
was 2,633 nM, whereas Tub2-BBBBB-containing yeast had an ED50 of just 21 nM. Thus,
some or all of these five amino acid substitutions are responsible for optimizing
microtubule-stabilizing interactions between EpoB and tubulin.
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To hone in on the specific interactions responsible for the cytotoxic effects of EpoB we
created variant tubulins by individually changing the five substitutions in Tub2-BBBBB
back to those found in yeast tubulin. These new variants showed a range of sensitivities.
Figure 2 represents the growth inhibition by EpoB from a single experiment, while Table 1
reports the results from three to five experiments for each tubulin variant. Compared to
Tub2-BBBBB yeast, the largest losses in cytotoxicity occurred when either the Lys19 or the
His227 of brain tubulin was back mutated to the Ala19 or Asn227 or yeast (Tub2-YBBBB
or Tub2-BBBYB). These single amino acid changes were each associated with a 13-fold
increase in ED50, respectively (Table 1). Yeast strains with individual brain-to-yeast back
mutations Val23Thr, Asp26Gly, or Phe270Tyr, on the other hand, showed only modest
decreases in cytotoxicity. The ED50 values of the Thr23, Gly26, or Tyr270 strains increased
~2-fold compared to cells with all five substitutions (50, 46, and 38 nM vs. 21 nM,
respectively). Thus, amino acids Lys19 and His227 contribute significantly to effective
interactions between tubulin and EpoB. However, the cumulative effect of the five
mutations was much greater than any single mutation.
Mutations in the taxane-binding region of β-tubulin do not increase inherent microtubule
stability
Although all five mutated amino acids lie within the EpoB binding pocket of tubulin, it is
possible that the mutations generally stabilize microtubules, either intrinsically or by
disrupting interactions with cellular regulators. This could render cells more sensitive to
microtubule stabilizers such as EpoB, resulting in an increase in cytotoxicity. To determine
whether the five mutations had stabilized microtubules independently of EpoB binding we
analyzed in vivo microtubule dynamics in cells containing Tub2-YYYYY or Tub2-BBBBB
in the absence of EpoB (Fig. 3). Overall, we found microtubule dynamics in the two strains
to be largely unaffected by the substitutions alone, suggesting the observed cytotoxicity is
due to EpoB-tubulin interactions (Table 2). The most notable changes in the Tub2-BBBBB
cells were a decrease in depolymerization rate and an increase in attenuation, which could
reflect slightly stabilized microtubules. However, this was accompanied by a decrease in
rescue frequency, relative to Tub2-YYYYY cells, which may reflect slightly destabilized
microtubules.
In order for inherent microtubule stability to be responsible for the graded cytotoxicity
profile, each mutation would likely contribute some degree of increased microtubule
stability. Previously, of 53 mutations created in an alanine-scanning analysis of yeast Tub1
(α-tubulin), only six (11%) produced detectable levels of resistance to the microtubule
destabilizing compound benomyl, suggestive of microtubule stabilization.[16] However, 37
mutations (70%) increased sensitivity to benomyl revealing that, overall, tubulin mutations
are more likely to destabilize rather than stabilize microtubules. Likewise, in our previous
systematic analysis of cysteine residues in Tub2, 17% of mutations resulted in increased
benomyl resistance while 42% caused increased benomyl sensitivity.[17] These results
support our conclusion that the increased EpoB cytotoxicity is directly due to increased
affinity of the drug to the mutated tubulins.
Molecular modeling correlates amino acid changes with EpoB cytotoxicity
Together, our cytotoxicity results and microtubule dynamics comparison demonstrate that
the five mutated residues differentially contribute to the binding affinity of EpoB for tubulin
and/or microtubules. To help interpret the changes in the EpoB ED50 values as a function of
the different binding site mutations, we performed molecular mechanics simulations based
on the EC and NMR structures using a yeast tubulin homology model. The binding scores
for EpoB interacting with the panel of tubulin mutants, presented in Table 3, were
determined using four different formulations, ChemScore,[18] DrugScore,[19] G-Score[20]
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and PMF.[21] The various scoring models generate different quantitative values due to the
fact that each takes into account a different set of physicochemical properties. Therefore,
scores for different mutants within a given formulation can be compared to understand the
relative contribution of each residue to EpoB binding. Also, this allows for correlating the
scores of each mutation in the EC and NMR models with the observed in vivo cytotoxicity
data.
The scores for both models largely predicted Tub2-YYYYY to exhibit the lowest affinity for
EpoB, while the bovine-like Tub2-BBBBB produced the highest ligand affinity.
Additionally, the scores for Tub2-YBBBB, the mutant with the lowest sensitivity, strikingly
discriminated between the EC and NMR binding modes across all four scoring models
(Table 3, bold text). In the EC model the scores for this mutant were close to those for Tub2-
BBBBB and ranged from the first to fourth highest ligand affinities of the tubulin variants
containing four of the five brain residues. Conversely, in the NMR model the values were
much closer to those for Tub2-YYYYY, and always predicted the lowest EpoB binding
affinity of the six tubulin mutants. Clearly, the NMR model more correctly predicted the
cytotoxicity data for Tub2-YBBBB.
In both models the scores for Tub2-BBBBY, Tub2-BBYBB, and Tub2-BYBBB correlated
well with the cytotoxicity data. The scores were closer to those for Tub2-BBBBB than to
Tub2-YYYYY. Also consistent with the cytotoxicity data is the fact that the scores for
Tub2-BBBYB were farther away from Tub2-BBBBB, and fell somewhere between the
scores for Tub2-BBBBB and Tub2-YYYYY. Of the two models, the binding scores
produced by the NMR model generally correlated better with the in vivo cytotoxicity data
across the range of tubulin variants (Table 3).
Variations in the predicted binding mode as a function of different tubulin mutants are
reported in Figure 4 for models assessed from NMR data (upper two quadrants) and EC
characterization (lower). These illustrations each focus on comparing the most potent
complex (EpoB bound to Tub2-BBBBB) with those of two specific tubulin variants: Tub2-
YBBBB (left side) and Tub2-BBBYB (right side). From these figures, one can perceive
clear differences in the predicted EpoB binding modes arising from the NMR and EC
models, however; there are also similarities across the two models in the types of EpoB-
tubulin interactions that are predicted to occur.
The fairly benign nature of the back-substitutions at residues 23, 26 and 270 can be
explained by the following analysis. In both the NMR and EC models, the sidechain methyls
of Val23 (Tub2-BBBBB) engage in favorable lipophilic interactions with EpoB that are not
fully matched by Thr23 (Tub2-BYBBB). In the NMR structure, both methyl carbons on
Val23 of Tub2-BBBBB are predicted to have lipophilic interactions with 11-methylene on
EpoB (4.03Å and 4.15Å respectively) whereas for Tub2-BYBBB, Thr23 has only one
sidechain methyl (at a distance of 4.05 Å) to produce a comparable interaction. In the EC
model, whereas both of the Val23 methyl groups have modest interactions with EpoB (one
with the 21-Me at 4.20 Å; the other with 26-Me at 4.58 Å), Thr23 appears to engage in no
favorable lipophilic interactions, instead only forming a possible weak H-bond between the
sidechain hydroxyl proton and the thiazole N of EpoB (3.77 Å). In the EC and NMR
models, the Asp26 Cα in Tub2-BBBBB approaches somewhat more closely to favorable
lipophilic contacts than does Gly26 Cα in Tub2-BBYBB (4.63 vs. 4.92 Å separation from
the thiazole in the EC model; 4.90 vs. 5.13 Å distance from 12-Me for the NMR complex).
Furthermore, the Asp26 Cβ (not present in Tub2-BBYBB) is also available for weak
lipophilic interactions in both models. The structure of the Tub2-BBBBY (Tyr270) complex
with EpoB is very similar to that observed for Tub2-BBBBB (Phe270) in both models,
however the very modest difference in EpoB potency upon mutation of this residue can be
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rationalized by slightly closer proximity between Phe270 and EpoB carbon atoms (EC: 3.91
Å; NMR: 3.73 Å) than is possible for Tyr270 (EC: 4.18 Å; NMR: 3.84 Å), with all other
aspects of the complexes being very closely conserved upon mutation. Together the
modeling and cytotoxicity data suggest that Phe270 does not mediate critical interactions
with EpoB. Consistent with this conclusion, a human ovarian carcinoma cell line with an
acquired Phe270Val mutation displayed 24-fold paclitaxel resistance yet only a 3-fold effect
on EpoB activity.[22]
The predicted structure for the Epothilone binding site in the yeast tubulin homology model
is marginally more spatially constricted than that resolved for bovine brain tubulin. Thus,
whereas prior studies have suggested close interactions between the EpoB thiazole ring and
the His227 residue in bovine brain tubulin,[7, 10, 13] such coupling may not be energetically
favored in the more constrained yeast tubulin receptor. Specifically, for a receptor model
based on the yeast tubulin sequence, we do not predict that the EpoB thiazole ring will
engage in H-bonding with the Asn227 residue present in wild-type yeast tubulin or in either
H-bonding or π-stacking with His227 present in the mutant forms. Rather, both the EC and
NMR models predict lipophilic interactions between the imidazole ring of His227 and the
EpoB macrocycle. In the EC model there is a 3.57 Å separation between the imidazole ring
and the 4-Me on EpoB for Tub2-BBBBB, and in the NMR model there is a 3.81 Å and 3.96
Å distance to the 4-Me and 6-Me, respectively. The lipophilic interactions between the
imidazole ring and the EpoB 4-Me or 6-Me are unavailable to the Asn227 residue in Tub2-
BBBYB. An additional difference evident in the NMR model is further EpoB stabilization
by His (as compared to Asn) via a methyl/π interaction with EpoB 16-Me (3.21 Å
separation).
Ala19 in Tub2-YBBBB does not have significant interactions with EpoB in either the NMR
or EC models, however the mutation to Lys19 affords favorable lipophilic contact in both
cases. Specifically, in the case of the EC model the methyl carbon located off the thiazole
ring approaches within 4.39 Å of Cγ on the Lys19 side chain, while in the NMR model, the
unsubstituted thiazole carbon is within 3.83 Å of Lys19 Cγ. In the latter case, there may
also be a modest electrostatic coupling between the lysine cationic N and the thiazole S
(4.22 Å separation).
From this analysis, it is apparent that both the NMR and EC models predict that similarly
favorable interactions, between EpoB and its high potency complex with Tub2-BBBBB, are
disrupted in the various back-mutational forms and the low potency Tub2-YYYYY receptor.
This is likely the reason that both the EC and NMR models produced consistently high
levels of correlation between computed binding scores and experimentally observed ED50
data (Table 3). While the predicted models we have generated herein do not lend definitive
corroboration to the NMR relative to the EC model, the NMR model better explains the
cytotoxicity results of the Tub2-YBBBB mutant and produced higher correlations with
observed in vivo results.
Summary
Determining the biologically relevant interactions between the taxanes/epothilones and
microtubules is an important goal. Current models of these interactions are based largely on
artificial systems (nonpolymerized tubulin[9, 10] and zinc-stabilized tubulin sheets[7, 8]).
Using in vivo microtubules as substrates we demonstrated that amino acids critical for
paclitaxel binding also strongly promote the cytotoxicity of EpoB, indicating that similar
interactions may mediate the toxicity of both compounds. However, the three substitutions
that were most critical for paclitaxel activity were least important for EpoB activity
(Thr23Val, Gly26Asp, Try270Phe) while the two substitutions dispensable to paclitaxel
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activity made the largest contributions to EpoB activity (Ala19Lys, Asn227His).[23]
Interestingly, this trend illustrates that fundamental differences in the binding interactions of
the two compounds also exist. Paclitaxel and EpoB have been shown to stimulate the in
vitro assembly of Tub2-BBBBB with similar activities.[14] Therefore, it is interesting that
yeast containing the modified tubulin were ~300-fold more sensitive to EpoB than reported
for paclitaxel, 21 nM versus 6500 nM,[23] respectively. Similar differences in human cells
result from inefficient export of EpoB by the ABC-transport protein P-glycoprotein.[3]
Correspondingly, perhaps paclitaxel, and not EpoB, is a substrate for any transport activity
remaining in the drug sensitized AD1-8 yeast strain.
Substoichiometric concentrations of both microtubule stabilizers[24] and inhibitors[25] are
known to suppress microtubule dynamics and stabilize the polymer, highlighting the
importance of understanding their interactions with dynamic microtubules. Moreover, assays
utilizing microtubule substrates in isogenic cells expressing endogenous levels of tubulin
will reflect important transitional conformations or specific interactions that may occur at
the ends of dynamic microtubules. Site directed mutagenesis of the taxane/epothilone-
binding pocket will likely reveal interactions critical to the active conformation and
biological activity of these important classes of compounds.
Experimental Section
Yeast strains and cytotoxicity
Yeast growth, genetic manipulations, and lithium acetate transformation were performed
using standard techniques.[26] Yeast strains used or created in this study are listed in Table 4.
To determine the in vivo efficacy of EpoB the Saccharomyces cerevisiae strain
AD12345678 (AD1-8)[27] which is deficient in seven drug transporters as well as one
transcription factor (pdr3) was transformed with a yeast genomic DNA fragment containing
the β-tubulin (TUB2) coding sequence with different subsets of the five amino acid changes
and a C-terminal His6 tag as previously described (Table 5).[15, 17] This transformation
strategy replaced the endogenous β-tubulin locus with the mutated version. The sensitivity
of each strain to EpoB was measured by comparing the growth of an equal number of cells
after 24–27 hours in rich media (YPD) at 30° C[15, 23] or by determining the doubling time
from the increase in O.D. 600 nm measured every 15 min in a Tecan Safire II plate reader
maintained at 30° C with continuous orbital mixing. The concentration of EpoB that
inhibited growth rate by 50%, the ED50, was determined from fitting the log(EpoB) versus
normalized growth rates by nonlinear regression using Prism software (Graphpad).
Fluorescence microscopy and microtubule dynamics analysis
In vivo analyses of microtubule dynamics in G1 (unbudded) cells were performed
essentially as described previously.[28] A control cell harboring an exogenous copy of GFP-
Tub1 (α-tubulin; pMG3)[28] under the TUB1 promoter was then transformed with fragments
to replace the endogenous TUB2 locus with either tub2-YYYYY-His6 or tub2-BBBBB-His6
(Table 5). Cells were grown to midlog phase in SD-complete media (0.67% yeast nitrogen
base without amino acids, 2% glucose, and supplemented with amino acids)[26] and placed
onto a microscope slide padded with 1% agarose in the same medium. Coverslips were
sealed using VALAP and epifluorescence time-lapse images of G1 cells were obtained on a
Zeiss AxioImager M2 microscope with a Piezo-electric driven Z-stage, 63X 1.4 NA
objective, Semrock filters, and a Coolsnap HQ2 CCD camera (Photometrics, Inc.) driven by
SlideBook software. Image series consisted of 8–10 Z-planes spaced 0.75 μm apart obtained
every six seconds for at least 6 minutes. The three dimensional length of individual astral
microtubules was subsequently determined at each timepoint using SlideBook software.
Polymerization and depolymerization events were defined as a line through at least four data
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points (24 s) that spanned a range of > 0.4 μm with an R2 value of ≥ 0.84. Periods of
attenuation were defined as persisting at least four data points with net length changes of < ±
0.2 μm. Data points that did not fit these criteria were discarded. The percentage of time
spent in each phase was determined by dividing the sum of the time in each phase by the
total classified time for all microtubules analyzed. Catastrophes were defined as a transition
into depolymerization following polymerization or attenuation. Rescues were defined as
transition out of depolymerization into polymerization or attenuation. Only the time spent
polymerizing or attenuated was considered to determine the catastrophe frequency.
Similarly, only time spent depolymerizing was considered to calculate rescue frequency.
Cells containing Tub2-YYYYY-His6 or Tub2-BBBBB-His6 (MGY981 or MGY982) were
imaged on three separate days. Cells were grown and maintained at 23° C during imaging. P
values were determined by Student’s t test.
Molecular modeling
Molecular mechanics simulations were based on a model of the structure of yeast beta
tubulin generated via the SwissModel[29] tool (according to default first-approach mode
specifications) based on the epothilone A/bovine brain tubulin electron diffraction crystal
structure.[7] Recognizing uncertainty in the real epothilone binding mode, we modeled one
scenario that assumed an EpoB binding mode as represented in the original crystallographic
structure and a second scenario designed to emulate the binding mode obtained by NMR
experiments of Carlomagno et al.[10] To prepare an EpoB-tubulin structure for evaluating
the effect of receptor mutations within the context of the original crystal structure, we used
SYBYL 8.1 (2009, Tripos, Inc., St. Louis MO) to modify the co-crystallized epothilone A
into EpoB (i.e., by substituting a methyl group for the proton on C12 of epothilone A), and
created estimated structures for the relevant mutants by substituting the corresponding
amino acids (Ala/Lys19, Thr/Val23, Gly/Asp26, Asn/His227, and Phe/Tyr270) via the
Biopolymer module in SYBYL. We constructed initial models representing the NMR-
predicted scenario in a similar manner with the exception that we modified the α-β-γ-δ-
torsion of His227 from 172.2° to 267.6° to support a potential π-stacking interaction with
the EpoB thiazole (instead of the previously assumed H-bond), and we repositioned the
ligand to encourage lipophilic interactions between the EpoB 4-Me groups and tubulin
residues Leu215, Leu228 and Leu273, and between the 6-Me group and Ala231 and
Phe270. This repositioning was accomplished by a short (1 ps) low temperature (200K)
molecular dynamics simulation in SYBYL via the Tripos molecular force field[30] and
Gasteiger-Marsili electrostatics[31] using weak (10 kcal/mol Å) constraints that held the
interacting carbon pairs (as mentioned above) within 3–5 Å of each other. Together the
seven tubulin variants (Tub2-BBBBB, Tub2-YBBBB, Tub2-BYBBB, Tub2-BBYBB, Tub2-
BBBYB, Tub2-BBBBY and Tub2-YYYYY) and two EpoB binding modes produced 14
EpoB/tubulin models.
To gauge the structural effects of each tubulin mutation on the EpoB binding modes, we
subjected each of the initial EpoB/tubulin models to molecular mechanics optimization. For
each complex, we permitted an unlimited number of optimization steps, employed very fine
criteria (maximum displacement of 0.001 Å; maximum ΔE of 0.0005 kcal/mol; gradient of
0.005 kcal/(mol Å)), and requested gradient recomputation after every geometry step. To
achieve these convergence criteria in a reasonable time, we assumed that the mutations
would have only a modest effect on the crystallographically resolved atomic coordinates of
conserved residues and thus relaxed only the ligand, plus residues 19, 23, 26, 227 and 270.
Based on results from our prior study on taxol interacting with mutations of β-tubulin,[23]
we chose to compare computational estimates for the relative EpoB potency in these
different receptors via the ChemScore,[18] DrugScore,[19] G-Score[20] and PMF[21]
formalisms for estimating the binding score.
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Structure of Epothilone B (EpoB).
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Growth inhibition by EpoB of S. cerevisiae strains with modified β-tubulin. The graph
depicts a representative experiment in which growth rates were monitored over 24 h in the
presence of increasing EpoB concentrations.
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Cytoplasmic microtubule dynamic behavior in G1 cells containing Tub2-YYYYY (top), and
Tub2-BBBBB (bottom). Two representative lifetime history plots (black & gray) depicting
the length of individual microtubules over time are presented for each condition.
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Comparisons between the computationally minimized structures for the complex of EpoB
bound to Tub2-BBBBB tubulin (grey structures in all panels) vs. EpoB in complex with the
Tub2-YBBBB (left-hand quadrants) or Tub2-BBBYB (right quadrants) tubulin mutants
(shown as green-colored sticks in all panels). The two top quadrants depict complexes
solved based on ligand-binding according to NMR characterization (12), while the two
bottom quadrants depict complexes derived from assuming binding modes analogous to the
EC prediction (9). All heteroatoms within the ligand (EpoB) and key receptor residues
(tubulin) are colored according to standard CPK coloring; tubulin secondary structure is
rendered as tan ribbons. Thick black arrows denote favorable interactions enjoyed by the
Tub2-BBBBB complex but absent for corresponding mutants. Thin dashed arrows are used
to indicate the position of residue 227.
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Table 1
EpoB ED50 values for S. cerevisiae strains with modified β-tubulin.
Tubulin form ED50, nM Relative cytotoxicity, ED50(YYYYY)/ED50
Tub2-BBBBB 21 ± 3 125
Tub2-BBBBY 38 ± 8 69
Tub2-BBYBB 46 ± 6 57
Tub2-BYBBB 50 ± 7 53
Tub2-BBBYB 276 ± 50 10
Tub2-YBBBB 277 ± 28 10
Tub2-YYYYY 2,633 ± 362 1
The cytotoxicity of epothilone B for the different yeast strains was determined as described in the methods. Each ED50 reflects the average
(±SEM) of three to five experiments.
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Table 2
Parameters of dynamic instability for cytoplasmic microtubules in vivo.
Tubulin form Tub2-BBBBB Tub2-YYYYY
Polymerization Rate (μm/min) 1.4 ± 0.7 (30) 1.7 ± 0.7 (33)
Depolymerization Rate (μm/min) 1.9 ± 0.7 (38)* 2.6 ± 1.2 (38)
Catastrophe Frequency (per min) 0.59 (28) 0.64 (29)
Rescue Frequency (per min) 1.07 (21) 1.33 (25)
Time spent polymerizing, % 24 29
Time spent depolymerizing, % 29 29
Time spent attenuated, % 46 42
polymerization duration, s 33 ± 13 (30) 34 ± 16 (33)
depolymerization duration, s 31 ± 15 (38) 30 ± 15 (33)
attenuation duration, s 44 ± 28 (44)* 34 ± 16 (49)
total microtubules observed 28 28
total time observed, s 4014 3858
Number of events is in parentheses. Rates/durations are presented as mean ± SD.
*
p < 0.05 compared to Tub2-YYYYY by unpaired, two-tailed t-test.
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Table 4
Yeast strains used in this study.
Strain Relevant genotype
AD1-8[27]
MATa, PDR1-3, ura3, his1, Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG, Dpdr3::hisG,
Dpdr15::hisG
MGY612 tub2-YYYYY-His6-URA3, otherwise isogenic to AD1-8
MGY613 tub2-BBBBB-His6-URA3, otherwise isogenic to AD1-8
MGY614 tub2-BBBBY-His6-URA3, otherwise isogenic to AD1-8
MGY615 tub2-BBBYB-His6-URA3, otherwise isogenic to AD1-8
MGY616 tub2-BBYBB-His6-URA3, otherwise isogenic to AD1-8
MGY617 tub2-BYBBB-His6-URA3, otherwise isogenic to AD1-8
MGY618 tub2-YBBBB-His6-URA3, otherwise isogenic to AD1-8
MGY981 MATa, tub2-YYYYY-His6-URA3, LEU2::GFP-TUB1::leu2D1
MGY982 MATa, tub2-BBBBB-His6-URA3, LEU2::GFP-TUB1::leu2D1
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Table 5
Specific mutations introduced to the epothilone binding pocket of yeast β-tubulin Tub2.
Tubulin form Specific mutations
Tub2-BBBBB A19K, T23V, G26D, N227H, Y270F, C-term His6
Tub2-BBBBY A19K, T23V, G26D, N227H, C-term His6
Tub2-BBBYB A19K, T23V, G26D, Y270F, C-term His6
Tub2-BBYBB A19K, T23V, N227H, Y270F, C-term His6
Tub2-BYBBB A19K, G26D, N227H, Y270F, C-term His6
Tub2-YBBBB T23V, G26D, N227H, Y270F, C-term His6
Tub2-YYYYY C-term His6
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